Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219193 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 641
- Enrollment target
NCT00219193 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 641 participants.
The verdict
NCT00219193, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 641 participants
- Enrollment target
Study Summary
To evaluate the blood pressure lowering effect and safety of the triple combination aliskiren / valsartan / HCTZ (300/320/25 mg) in patients with essential hypertension not adequately responsive to HCTZ 25 mg
Interventions
- DRUG aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 641 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00219193
The ClinicalTrials.gov registry entry for NCT00219193 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 641 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aliskiren is the first listed.
NCT00219193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00219193 about?
NCT00219193 is a clinical study titled "A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients". To evaluate the blood pressure lowering effect and safety of the triple combination aliskiren / valsartan / HCTZ (300/320/25 mg) in patients with essential hypertension not adequately responsive to HCTZ 25 mg
What is the current status of trial NCT00219193?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 641 participants. The study started on 2005-10. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00219193?
The interventions under investigation include: aliskiren (DRUG).
Who is sponsoring clinical trial NCT00219193?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.